FOLH1 and prostate cancer: In patients with prostate cancer, prostate-specific membrane antigen (PSMA)-PET/CT-guided RT proves invaluable for initial tumor staging, local recurrence, and detection of oligometastatic disease (≤ 5 lesions) or metastatic progression, thus playing a crucial role in treatment planning [4–6].